Your browser doesn't support javascript.
loading
Modes of action insights from the crystallographic structures of retinoic acid receptor-related orphan receptor-γt (RORγt).
Zhang, Junjie; Chen, Baiyu; Zhang, Chao; Sun, Nannan; Huang, Xiaoqin; Wang, Wuqing; Fu, Wei.
Affiliation
  • Zhang J; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
  • Chen B; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
  • Zhang C; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
  • Sun N; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
  • Huang X; Center for Research Computing, Office of Information Technology, Center for Theoretical Biological Physics, Rice University, Houston, TX, 77030, USA.
  • Wang W; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
  • Fu W; School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China. Electronic address: wfu@fudan.edu.cn.
Eur J Med Chem ; 247: 115039, 2023 Feb 05.
Article in En | MEDLINE | ID: mdl-36566711
ABSTRACT
RORγt plays an important role in mediating IL-17 production and some tumor cells. It has four functional domains, of which the ligand-binding domain (LBD) is responsible for binding agonists to recruit co-activators or inverse agonists to prevent co-activator recruiting the agonists. Thus, potent ligands targeting the LBD of this protein could provide novel treatments for cancer and autoimmune diseases. In this perspective, we summarized and discussed various modes of action (MOA) of RORγt-ligand binding structures. The ligands can bind with RORγt at either orthosteric site or the allosteric site, and the binding modes at these two sites are different for agonists and inverse agonist. At the orthosteric site, the binding of agonist is to stabilize the H479-Y502-F506 triplet interaction network of RORγt. The binding of inverse agonist features as these four apparent ways (1) blocking the entrance of the agonist pocket in RORγt; (2) directly breaking the H479-Y502 pair interactions; (3) destabilizing the triplet H479-Y502-F506 interaction network through perturbing the conformation of the side chain in M358 at the bottom of the binding pocket; (4) and destabilizing the triplet H479-Y502-F506 through changing the conformation of the side chain of residue W317 side chain. At the allosteric site of RORγt, the binding of inverse agonist was found recently to inhibit the activation of protein by interacting directly with H12, which results in unfolding of helix 11' and orientation of H12 to directly block cofactor peptide binding. This overview of recent advances in the RORγt structures is expected to provide a guidance of designing more potent drugs to treat RORγt-related diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Inverse Agonism / Nuclear Receptor Subfamily 1, Group F, Member 3 Type of study: Guideline Language: En Journal: Eur J Med Chem Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Inverse Agonism / Nuclear Receptor Subfamily 1, Group F, Member 3 Type of study: Guideline Language: En Journal: Eur J Med Chem Year: 2023 Document type: Article